CD8A and neoplasm: Meanwhile, Koji Takada et al. also showed that tumor-infiltrating CD8 to FOXP3 lymphocyte ratio may predict treatment responses of dual target combination therapy [5], but which is invasive and difficult to be accepted by patients.